SEC 8-K News



2024-12-09 16:23:17

Achieve Life Sciences, Inc. has announced the appointment of Mark K. Oki as the new Chief Financial Officer, effective as of December 5, 2024. Mr. Oki's previous experience includes serving as CFO for Aytu Biopharma, Inc., Vivus LLC, and Alexza Pharmaceuticals, Inc., with earlier roles at Pharmacyclics, Inc. and Incyte Genomics, Inc., and beginning his career at Deloitte & Touche, LLP. His employment agreement with Achieve Life Sciences includes an initial annual base salary of $450,000, eligibility for a discretionary annual bonus, equity incentives, severance provisions, and healthcare benefits. There are no familial or material transactional relationships between Mr. Oki and the company's executives or directors.

  • Achieve Life Sciences, Inc.
  • Mark K. Oki
  • Aytu Biopharma, Inc.
  • Vivus LLC (formerly Vivus Inc.)
  • Alexza Pharmaceuticals, Inc.
  • Pharmacyclics, Inc.
  • Incyte Genomics, Inc. (now Incyte Corporation)
  • Deloitte & Touche, LLP (now Deloitte)
  • San Jose State University